BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, Limwattananon P, Sawanyawisuth K. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. Pharmacoeconomics 2019;37:279-89. [PMID: 30387074 DOI: 10.1007/s40273-018-0741-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ng SS, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand. Thromb Res 2020;185:63-71. [PMID: 31770689 DOI: 10.1016/j.thromres.2019.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
3 Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaiyakunapruk N, McEvoy M, Attia J, Thakkinstian A. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care 2020;8:e001020. [PMID: 32690574 DOI: 10.1136/bmjdrc-2019-001020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
4 Wang CY, Pham PN, Thai TN, Brown JD. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. Pharmacoeconomics 2020;38:1333-43. [PMID: 32924092 DOI: 10.1007/s40273-020-00960-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Azahar SN, Sulong S, Wan Zaidi WA, Muhammad N, Kamisah Y, Masbah N. Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study. IJERPH 2022;19:1078. [DOI: 10.3390/ijerph19031078] [Reference Citation Analysis]
6 Dilokthornsakul P, Permsuwan U. The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis. Expert Rev Pharmacoecon Outcomes Res 2021;:1-8. [PMID: 33504221 DOI: 10.1080/14737167.2021.1883429] [Reference Citation Analysis]